Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist

Kabirullah Lutfy, Ke Zhong Shen, Ik Sung Kwon, Sui Xiong Cai, Richard M. Woodward, John F.W. Keana, Eckard Weber

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Recent studies indicate that competitive and non-competitive NMDA receptor antagonists can block the development of morphine tolerance. Since glycine is considered to be a co-agonist for activation of NMDA receptors we examined the effect of a novel bioavailable NMDA receptor/glycine site antagonist, 5-nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1328), on the development of morphine tolerance. Administration of ACEA-1328 (20 mg/kg) completely blocked tolerance to morphine-induced antinociception in the tail flick test in CD-1 mice, without affecting the basal nociceptive response or potentiating morphine-induced antinociceptive effects. These data suggest that inhibition of NMDA receptor activity via blockade of the glycine co-agonist site is potentially viable as a therapeutic approach for preventing development of morphine tolerance.

Original languageEnglish (US)
Pages (from-to)187-189
Number of pages3
JournalEuropean Journal of Pharmacology
Volume273
Issue number1-2
DOIs
StatePublished - Jan 24 1995

Keywords

  • (CD-1 mouse)
  • Morphine tolerance
  • NMDA receptor/glycine site antagonist
  • Tail flick test

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist'. Together they form a unique fingerprint.

  • Cite this

    Lutfy, K., Shen, K. Z., Kwon, I. S., Cai, S. X., Woodward, R. M., Keana, J. F. W., & Weber, E. (1995). Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist. European Journal of Pharmacology, 273(1-2), 187-189. https://doi.org/10.1016/0014-2999(94)00716-K